IngenioRx, UC’s new pharmacy benefit plan manager, to begin on May 1
On May 1, 2019, IngenioRx (an Anthem company) will replace ExpressScripts as the pharmacy benefit plan manager for UC medical plan members
On May 1, 2019, IngenioRx (an Anthem company) will replace ExpressScripts as the pharmacy benefit plan manager for UC medical plan members. This transition will provide UC medical plan members with 24/7/365 customer service access along with improved online services and information.
There are no changes to UC medical or pharmacy plans as a result of this change and plan members can continue to use the same retail pharmacies used today for pharmacy purchases. Individuals currently taking advantage of home delivery or who use specialty medications will receive additional communications directly from Anthem in the coming weeks.
Additional information is available on the Anthem Medical Plan Options page.
Questions?
Plan members with questions are welcome to contact Anthem at the phone number on their ID card.
Have additional questions? Reach out to the UC Benefits team at benefits@uc.edu or call 513-556-6381.
Related Stories
Recent advances may speed time to endometriosis diagnosis
March 16, 2026
The average time to clinical diagnosis of endometriosis is nine years. Definitive diagnosis of the disease is difficult, and until recently, has relied on laparoscopic surgery. Now, as Medscape recently reported, novel clinical recommendations, advanced diagnostic tools and research into inflammation and immune responses, are bringing promise that women with endometriosis will find relief sooner and without surgery, according to experts, including Katie Burns, PhD, University of Cincinnati College of Medicine associate professor.
Local media highlight completion of Blood Cancer Healing Center fourth and fifth floors
March 16, 2026
Local media including WLWT and the Cincinnati Business Courier highlighted the opening of research laboratories and the UC Osher Wellness Suite and Learning Kitchen at the University of Cincinnati Cancer Center’s Blood Cancer Healing Center.
Trial results support weekly buprenorphine treatment of opioid use disorder during pregnancy
March 16, 2026
Supported by the National Institutes of Health (NIH), researchers led by the University of Cincinnati's John Winhusen published clinical trial results in JAMA Internal Medicine that found administering weekly injectable extended-release buprenorphine for treatment of opioid use disorder during pregnancy led to higher rates of abstinence from illicit opioids than buprenorphine given daily under the tongue, one of the standard methods of treatment.